Mizuho Securities Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Cuts Target Price to $49

Mizuho Securities analyst Graig Suvannavejh maintains $Apellis Pharmaceuticals(APLS.US)$ with a hold rating, and adjusts the target price from $52 to $49.According to TipRanks data, the analyst has a

Moomoo NewsJul 1 11:32 ET · Ratings

Express News | Apellis Pharmaceuticals Inc : Mizuho Cuts Target Price to $49 From $52

ReutersJul 1 00:53 ET

BofA Securities Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Maintains Target Price $82

BofA Securities analyst Tazeen Ahmad maintains $Apellis Pharmaceuticals(APLS.US)$ with a buy rating, and maintains the target price at $82.According to TipRanks data, the analyst has a success rate of

Moomoo NewsJun 29 09:32 ET · Ratings

Sector Update: Health Care Stocks Edge Higher in Afternoon Trading

Health care stocks were edging up Friday afternoon, with the NYSE Health Care Index rising 0.2% and the Health Care Select Sector SPDR Fund (XLV) up less than 0.1%. The iShares Biotechnology ETF (IBB)

MT NewswiresJun 28 14:07 ET

Express News | Baird Maintains Outperform on Apellis Pharmaceuticals, Maintains $100 Price Target

BenzingaJun 28 13:10 ET

Apellis Pharmaceuticals Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/28/2024 161.03% Baird $100 → $100 Maintains Outperform 05/31/2024 20.07% Piper Sandler → $46 Initiates

BenzingaJun 28 13:09 ET